Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 163, Issue 1, Pages 93-103Publisher
WILEY
DOI: 10.1111/bjh.12489
Keywords
clinical outcome; MAPK1; paediatric acute lymphoblastic leukaemia; prednisolone; MIR335
Categories
Funding
- National Medical Research Council (NMRC)
- Singapore National Research Foundation
- Ministry of Education under Research Centre of Excellence Programme
- NMRC Clinician Scientist Investigator award
Ask authors/readers for more resources
Acute lymphoblastic leukaemia (ALL) is the most common paediatric malignancy. Although 90% of patients are now long-term survivors, the remaining 10% have poor outcome predominantly due to drug resistance. In this study, we carried out genome-wide microRNA (miRNA) microarray analysis on diagnostic bone marrow samples to determine miRNA expression profiles associated with poor outcome in ALL. A reduced expression of MIR335 was identified as the most significant miRNA abnormality associated with poor outcome. It is well known that glucocorticoid (GC) resistance is one of the major reasons contributing to poor outcome. We show that exogenous expression of MIR335 in ALL cells increases sensitization to prednisolone-mediated apoptosis. Moreover, we demonstrate that MAPK1 is a novel target of MIR335, and that MEK/ERK inhibitor treatment enhanced prednisolone-induced cell death through the activation of BIM (BCL2L11). These results provide a possible underlying molecular mechanism to explain the association between reduced MIR335 with poor clinical outcome, and suggest that approaches to re-introduce MIR335 expression or override MAPK1 activity may offer promising therapeutic strategies in the treatment of ALL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available